​

C4 Therapeutics (CCCC) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

C4 Therapeutics Revenue Highlights

Latest Revenue (Y)

$20.76M

Latest Revenue (Q)

$5.18M

C4 Therapeutics Revenue by Period

C4 Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$20.76M-33.25%
2022-12-31$31.10M-32.08%
2021-12-31$45.78M37.93%
2020-12-31$33.20M55.25%
2019-12-31$21.38M10.42%
2018-12-31$19.36M-

C4 Therapeutics generated $20.76M in revenue during NA 2023, up -33.25% compared to the previous quarter, and up 107.19% compared to the same period a year ago.

C4 Therapeutics Revenue by Quarter

DateRevenueChange
2024-12-31$5.18M-66.30%
2024-09-30$15.36M27.95%
2024-06-30$12.01M295.06%
2024-03-31$3.04M-6.81%
2023-12-31$3.26M-70.55%
2023-09-30$11.07M315.62%
2023-06-30$2.66M-29.13%
2023-03-31$3.76M31.71%
2022-12-31$2.85M-57.74%
2022-09-30$6.75M-51.18%
2022-06-30$13.83M80.74%
2022-03-31$7.65M-61.88%
2021-12-31$20.08M136.21%
2021-09-30$8.50M-13.10%
2021-06-30$9.78M31.71%
2021-03-31$7.43M-10.12%
2020-12-31$8.26M-2.19%
2020-09-30$8.45M-12.65%
2020-06-30$9.67M41.87%
2020-03-31$6.82M-16.97%
2019-12-31$8.21M53.04%
2019-09-30$5.36M37.42%
2019-06-30$3.90M-
2019-03-31$3.90M-

C4 Therapeutics generated $5.18M in revenue during Q3 2024, up -66.30% compared to the previous quarter, and up 46.76% compared to the same period a year ago.

C4 Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ARVNArvinas$263.40M$188.80M
GLUEMonte Rosa Therapeutics$75.62M$60.65M
NRIXNurix Therapeutics$54.55M$18.45M
KYMRKymera Therapeutics$47.07M$7.39M
FHTXFoghorn Therapeutics$22.60M$2.86M
CCCCC4 Therapeutics$20.76M$5.18M
IPSCCentury Therapeutics$6.59M$109.16M
STTKShattuck Labs$5.72M-
CGEMCullinan Oncology--
RZLTRezolute--
RVMDRevolution Medicines--
EWTXEdgewise Therapeutics--
PRLDPrelude Therapeutics-$4.00M
MLYSMineralys Therapeutics--

CCCC Revenue FAQ

What is C4 Therapeutics’s yearly revenue?

C4 Therapeutics's yearly revenue for 2023 was $20.76M, representing a decrease of -33.25% compared to 2022. The company's yearly revenue for 2022 was $31.1M, representing a decrease of -32.08% compared to 2021. CCCC's yearly revenue for 2021 was $45.78M, representing an increase of 37.93% compared to 2020.

What is C4 Therapeutics’s quarterly revenue?

C4 Therapeutics's quarterly revenue for Q3 2024 was $5.18M, a -66.30% decrease from the previous quarter (Q2 2024), and a 58.75% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $15.36M, a 27.95% increase from the previous quarter (Q1 2024), and a 38.75% increase year-over-year (Q2 2023). CCCC's quarterly revenue for Q1 2024 was $12.01M, a 295.06% increase from the previous quarter (Q4 2023), and a 350.68% increase year-over-year (Q1 2023).

What is C4 Therapeutics’s revenue growth rate?

C4 Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -54.67%, and for the last 5 years (2019-2023) was -2.92%.